Coupon Accepted Successfully!


Recent Advances

Recent Advances = Newer Drugs

Peginterferon alfa -2a

(IN- alpha + polyethelene)

Chronic hepatitis C

Voriconazole (azole Antifungal)

Acute invasice asperigillosis

Scedosporium apiosperum Fusarium spp

Adefovir (anti – HBV)

Active HBV infection

Interferon beta -1a

Relapsing multiple sclerosis

Enfuritide (fusion inhibitor)

(Blocks viral entry in CD4 cells)

Anti – HIV drug

Terbinafine (Allylamine – Antifungal (DOC)


Miltifosine (SH donating agent)

Leishmaniasis (most effective agent so far)

Atovaquinone (Antimalarial)

Malarial prophylaxis

Tiprinavir (protease inhibitor)

Hepatitis B

Entecavir (protease inhibitor)

Hepatitis B infection


NNRTI (HIV-1 inhibitor)

Darunavir (HIV-1 protease inhibitor)

Refractory HIV

Recent Advances: Antimicrobials:
Bedaquiline: It is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Inhibits mycobacterial ATP (adenosine 5'-triphosphate) synthase, an enzyme that is essential for the generation of energy in Mycobacterium tuberculosis.
Raltegravir: Integrase inhibitor, which inhibits the integration of viral complimentary DNA into the host genome. In combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
Fidaxomicin: a macrocyclic antibiotics approved for C. difficile infection
Rilpivirine: A newer non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1).
Ceftaroline fosamil: A fifth generation cephalosporin with activity against both gram-positive and gram-negative microorganisms. It is approved for the treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection, including cases caused by methicillin-resistant Staphylococcus aureus (MRSA)

Test Your Skills Now!
Take a Quiz now
Reviewer Name